|
gptkbp:instanceOf
|
gptkb:drug
antipsychotic medication
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05AX13
|
|
gptkbp:brand
|
gptkb:Invega
gptkb:Invega_Sustenna
gptkb:Invega_Trinza
|
|
gptkbp:CASNumber
|
144598-75-4
|
|
gptkbp:chemicalFormula
|
C23H27FN4O3
|
|
gptkbp:contraindication
|
hypersensitivity to paliperidone
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
23 hours (oral)
25-49 days (injection)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
paliperidone
|
|
gptkbp:IUPACName
|
(RS)-3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
|
|
gptkbp:KEGGID
|
D05363
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:metabolism
|
minimal hepatic metabolism
|
|
gptkbp:molecularWeight
|
426.48 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
115237
103040
DB01267
|
|
gptkbp:relatedTo
|
gptkb:risperidone
|
|
gptkbp:riskFactor
|
gptkb:orthostatic_hypotension
neuroleptic malignant syndrome
tardive dyskinesia
hyperglycemia
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
weight gain
QT prolongation
drowsiness
tachycardia
extrapyramidal symptoms
increased prolactin
|
|
gptkbp:synonym
|
9-hydroxyrisperidone
|
|
gptkbp:UNII
|
J2U8L2A955
|
|
gptkbp:usedFor
|
gptkb:schizoaffective_disorder
schizophrenia
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Invega
|
|
gptkbp:bfsLayer
|
6
|